crc-22-0265-s05.pptx (5.54 MB)

Figure S4 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells

figure

posted on 2023-05-25, 14:20 authored by S.M. Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L. Good, Rigel J. Kishton, Biman C. Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M. Bedanova, Chengyu Liu, Michael J. Kruhlak, Nicholas P. Restifo, Raul Vizcardo

Figure S4: Characterization of tumor antigen specific TIL-iPSC clone derived from patient 3784

Funding

HHS | NIH | NCI | Cancer Moonshot (Misión contra el Cáncer)

HHS | NIH | NHLBI | NHLBI Division of Intramural Research (DIR)

History

ARTICLE ABSTRACT

Reprogramming of TIL into iPSC holds great promise for the future treatment of cancer due to their rejuvenated nature and the retention of tumor-specific TCRs. One limitation is the lack of selective and efficient methods for reprogramming tumor-specific T cells from polyclonal TIL. Here we addressed this limitation and present a method to efficiently reprogram TIL into iPSC colonies carrying diverse tumor antigen reactive TCR recombination.

Usage metrics

Keywords

Immunotherapy Cellular immunotherapy Stem Cell Biology iPS cells Biological Agents & Therapies Stem cell therapies Immunology Tumor antigens/neoantigens

Licence

CC BY